價格 | ¥490 | ¥718 | ¥997 |
包裝 | 1mg | 2mg | 5mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱:化合物 TAK-960 | 英文名稱:TAK-960 |
CAS:1137868-52-0 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 97.06% | 產(chǎn)品類別: 抑制劑 |
貨號: T7200 |
名稱 | TAK-960 |
描述 | TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC50 values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively. |
細胞實驗 | Fifty-five CRC cell lines and 18 PDX models were exposed to TAK-960 and evaluated for proliferation (IC50) and Tumor Growth Inhibition Index, respectively.?Additionally, 2 KRAS wild type and 2 KRAS mutant PDX models were treated with TAK-960 as single agent or in combination with cetuximab or irinotecan.?TAK-960 mechanism of action was elucidated through immunoblotting and cell cycle analysis[1]. |
體外活性 | CRC cell lines demonstrated a variable anti-proliferative response to TAK-960 with IC50 values ranging from 0.001 to >?0.75 μmol/L. Anti-proliferative effects were sustained after removal of drug. Following TAK-960 treatment a highly variable accumulation of mitotic (indicating cell cycle arrest) and apoptotic markers was observed. TAK-960 treatment induced G2/M arrest and polyploidy. Six out of the eighteen PDX models responded to single agent TAK-960 therapy (TGII20). The addition of TAK-960 to standard of care chemotherapy resulted in largely additive antitumor effects[1]. |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 35 mg/mL (62.32 mM) |
關鍵字 | Polo-like Kinase (PLK) | TAK960 | cell | TAK 960 | cancer | proliferation | Inhibitor | mitosis | leukemia | inhibit | phosphorylation | lines | TAK-960 |
相關產(chǎn)品 | Onvansertib | T521 | Poloxin-2 | SBE13 Hydrochloride | Pyridoxine | (E/Z)-Rigosertib sodium | Plogosertib | BI 2536 | Ro3280 | 3MB-PP1 | Rigosertib sodium | Cyclapolin 9 |
相關庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 抗癌活性化合物庫 | 已知活性化合物庫 | 激酶抑制劑庫 | NO PAINS 化合物庫 | 臨床期小分子藥物庫 | 藥物功能重定位化合物庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學,分子砌塊,生物技術服務 | 經(jīng)營模式 | 貿易,工廠,試劑,定制,服務 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP6年
|
上海澤葉生物科技有限公司
|
2025-02-12 | |
¥5500 |
VIP1年
|
本溪市佳宜生物商貿有限公司
|
2024-12-30 | |
¥7003.90 |
VIP2年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 | |
¥1200 |
南京百鑫德諾生物科技有限公司
|
2024-09-26 |